SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mehmet A.N. Sendur, Nurullah Zengin, Sercan Aksoy, Kadri Altundag, Everolimus: a new hope for patients with breast cancer, Current Medical Research and Opinion, 2014, 30, 1, 75

    CrossRef

  2. 2
    Parvin F. Peddi, Rebecca A. Shatsky, Sara A. Hurvitz, Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer, Cancer Treatment Reviews, 2014, 40, 2, 320

    CrossRef

  3. 3
    Claudia Omarini, Eirini Thanopoulou, Stephen R. D. Johnston, Pneumonitis and pulmonary fibrosis associated with breast cancer treatments, Breast Cancer Research and Treatment, 2014, 146, 2, 245

    CrossRef

  4. 4
    Eilin Austreid, Per Eystein Lonning, Hans Petter Eikesdal, The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy, Expert Opinion on Pharmacotherapy, 2014, 15, 5, 681

    CrossRef

  5. 5
    Matthew G. Fury, Eric Sherman, Alan L. Ho, Han Xiao, Frank Tsai, Oby Nwankwo, Camelia Sima, Adrian Heguy, Nora Katabi, Sofia Haque, David G. Pfister, A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer, Cancer, 2013, 119, 10
  6. 6
    Elisavet Paplomata, Amelia Zelnak, Ruth O’Regan, Everolimus: side effect profile and management of toxicities in breast cancer, Breast Cancer Research and Treatment, 2013, 140, 3, 453

    CrossRef

  7. 7
    Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Martin Filipits, Rupert Bartsch, mTOR inhibitors in breast cancer: A systematic review, Gynecologic Oncology, 2012, 127, 3, 662

    CrossRef